Advertisement

Short-term exposure to desert dust and the risk of acute myocardial infarction in Japan: a time-stratified case-crossover study

  • 34 Accesses

Abstract

Particulate matter from natural sources such as desert dust causes harmful effects for health. Asian dust (AD) increases the risk of acute myocardial infarction (AMI). However, little is known about the risk of myocardial infarction with nonobstructive coronary arteries (MINOCA), compared to myocardial infarction with coronary artery disease (MI-CAD). Using a time-stratified case-crossover design and conditional logistic regression models, the association between short-term exposure to AD whereby decreased visibility (< 10 km) observed at each monitoring station nearest to the hospitals was used for exposure measurements and admission for AMI in the spring was investigated using a nationwide administrative database between April 2012 and March 2016. According to presence of revascularization and coronary atherosclerosis, AMI patients (n = 30,435) were divided into 2 subtypes: MI-CAD (n = 27,202) or MINOCA (n = 3233). The single lag day-2 was used in AD exposure based on the lag effect analysis. The average level of meteorological variables and co-pollutants on the 3 days prior to the case/control days were used as covariates. The occurrence of AD events 2 days before the admission was associated with admission for MINOCA after adjustment for meteorological variables [odds ratio 1.65; 95% confidence interval (CI) 1.18–2.29], while the association was not observed in MI-CAD. The absolute risk difference of MINOCA admission was 1.79 (95% CI 1.21–2.38) per 100,000 person-year. These associations between AD exposure and the admission for MINOCA remained unchanged in two-pollutant models. This study provides evidence that short-term exposure to AD is associated with a higher risk of MINOCA, but not MI-CAD.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2

References

  1. 1.

    Di Q, Wang Y, Zanobetti A, et al. Air pollution and mortality in the Medicare population. N Engl J Med. 2017;376:2513–22.

  2. 2.

    Di Q, Dai L, Wang Y, et al. Association of short-term exposure to air pollution with mortality in older adults. JAMA. 2017;318:2446–56.

  3. 3.

    Yamazaki S, Shima M, Yoda Y, et al. Exposure to air pollution and meteorological factors associated with children’s primary care visits at night due to asthma attack: case-crossover design for 3-year pooled patients. BMJ Open. 2015;5:e005736.

  4. 4.

    Nuvolone D, Balzi D, Chini M, Scala D, Giovannini F, Barchielli A. Short-term association between ambient air pollution and risk of hospitalization for acute myocardial infarction: results of the cardiovascular risk and air pollution in Tuscany (RISCAT) study. Am J Epidemiol. 2011;174:63–71.

  5. 5.

    Peters A, Dockery DW, Muller JE, Mittleman MA. Increased particulate air pollution and the triggering of myocardial infarction. Circulation. 2001;103:2810–5.

  6. 6.

    Mustafic H, Jabre P, Caussin C, et al. Main air pollutants and myocardial infarction: a systematic review and meta-analysis. JAMA. 2012;307:713–21.

  7. 7.

    Cohen AJ, Brauer M, Burnett R, et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet. 2017;389:1907–18.

  8. 8.

    Kojima S, Michikawa T, Ueda K, et al. Asian dust exposure triggers acute myocardial infarction. Eur Heart J. 2017;38:3202–8.

  9. 9.

    Matsukawa R, Michikawa T, Ueda K, et al. Desert dust is a risk factor for the incidence of acute myocardial infarction in Western Japan. Circ Cardiovasc Qual Outcomes. 2014;7:743–8.

  10. 10.

    Choi JC, Lee M, Chun Y, Kim J, Oh S. Chemical composition and source signature of spring aerosol in Seoul, Korea. J Geophys Res Atmos. 2001;106:18067–74.

  11. 11.

    Ichinose T, Yoshida S, Hiyoshi K, et al. The effects of microbial materials adhered to Asian sand dust on allergic lung inflammation. Arch Environ Contam Toxicol. 2008;55:348–57.

  12. 12.

    Lei YC, Chan CC, Wang PY, Lee CT, Cheng TJ. Effects of Asian dust event particles on inflammation markers in peripheral blood and bronchoalveolar lavage in pulmonary hypertensive rats. Environ Res. 2004;95:71–6.

  13. 13.

    Rattanapinyopituk K, Shimada A, Morita T, et al. Ultrastructural changes in the air-blood barrier in mice after intratracheal instillations of Asian sand dust and gold nanoparticles. Exp Toxicol Pathol. 2013;65:1043–51.

  14. 14.

    Higashisaka K, Fujimura M, Taira M, et al. Asian dust particles induce macrophage inflammatory responses via mitogen-activated protein kinase activation and reactive oxygen species production. J Immunol Res. 2014;2014:856154.

  15. 15.

    Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72:2231–64.

  16. 16.

    Beltrame JF. Assessing patients with myocardial infarction and nonobstructed coronary arteries (MINOCA). J Intern Med. 2013;273:182–5.

  17. 17.

    Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation. 2015;131:861–70.

  18. 18.

    Pasupathy S, Tavella R, Beltrame JF. The what, when, who, why, how and where of myocardial infarction with non-obstructive coronary arteries (MINOCA). Circ J. 2016;80:11–6.

  19. 19.

    Pasupathy S, Tavella R, Beltrame JF. Myocardial infarction with nonobstructive coronary arteries (MINOCA): the past, present, and future management. Circulation. 2017;135:1490–3.

  20. 20.

    Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38:143–53.

  21. 21.

    Yasuda S, Nakao K, Nishimura K, et al. The current status of cardiovascular medicine in Japan—analysis of a large number of health records from a nationwide claim-based database, JROAD-DPC. Circ J. 2016;80:2327–35.

  22. 22.

    Kanaoka K, Okayama S, Yoneyama K, et al. Number of board-certified cardiologists and acute myocardial infarction-related mortality in Japan—JROAD and JROAD-DPC registry analysis. Circ J. 2018;82:2845–2851.

  23. 23.

    Yasuda S, Miyamoto Y, Ogawa H. Current status of cardiovascular medicine in the aging society of Japan. Circulation. 2018;138:965–7.

  24. 24.

    Janes H, Sheppard L, Lumley T. Case-crossover analyses of air pollution exposure data: referent selection strategies and their implications for bias. Epidemiology. 2005;16:717–26.

  25. 25.

    Yamaji K, Kohsaka S, Morimoto T, et al. Relation of ST-segment elevation myocardial infarction to daily ambient temperature and air pollutant levels in a japanese nationwide percutaneous coronary intervention registry. Am J Cardiol. 2017;119:872–80.

  26. 26.

    Kinjo K, Sato H, Sato H, et al. Circadian variation of the onset of acute myocardial infarction in the Osaka area, 1998–1999: characterization of morning and nighttime peaks. Jpn Circ J. 2001;65:617–20.

  27. 27.

    Chang CC, Hwang JS, Chan CC, Wang PY, Cheng TJ. Effects of concentrated ambient particles on heart rate, blood pressure, and cardiac contractility in spontaneously hypertensive rats during a dust storm event. Inhal Toxicol. 2007;19:973–8.

  28. 28.

    Kono T, Sabbah HN. Takotsubo cardiomyopathy. Heart Fail Rev. 2014;19:585–93.

  29. 29.

    Hung MJ, Hu P, Hung MY. Coronary artery spasm: review and update. Int J Med Sci. 2014;11:1161–71.

  30. 30.

    Saw J. Spontaneous coronary artery dissection. Can J Cardiol. 2013;29:1027–33.

  31. 31.

    Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476–82.

  32. 32.

    Ishii M, Kaikita K, Sakamoto K, et al. Characteristics and in-hospital mortality of patients with myocardial infarction in the absence of obstructive coronary artery disease in super-aging society. Int J Cardiol. 2019. https://doi.org/10.1016/j.ijcard.2019.09.037.

  33. 33.

    Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med. 1993;329:1677–83.

Download references

Author information

Correspondence to Koji Kawakami.

Ethics declarations

Conflict of interest

All authors declare no potential conflict of interest in connection with this paper and have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Dr. Seki reports personal fees from Pfizer.inc., outside the submitted work. Dr. Kaikita reports grants and other from Bayer Yakuhin, Ltd., grants and other from Daiichi Sankyo Co., Ltd., grants from Novartis Pharma K.K., grants from SBI pharma K.K., from null, outside the submitted work. Dr. Sakamoto reports grants from Daiichi-Sankyo Co., Ltd., outside the submitted work. Dr. Yasuda reports grant support from Takeda and Abbott, and lecture fees from Daiichi Sankyo and Bristol-Myers Squibb. Dr. Saito reports grants and personal fees from Bayer Holding Ltd, grants from Terumo Corporation, grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants from Amgen Astellas BioPharma K.K., grants and personal fees from Novartis Pharma K.K., grants and personal fees from Ono Pharmatical Co., Ltd, grants and personal fees from Shionogi & Co., Ltd, grants and personal fees from Teijin Pharma Ltd., grants from St. Jude Medical Japan Co., Ltd., grants and personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Astellas Pharma Inc., personal fees from Asahi Kasei Pharma Corporation, personal fees from Actelion Pharmaceuticals Japan Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Daiichi Sankyo Co., Ltd., personal fees from Dainippon Sumitomo Pharma Co., Ltd., personal fees from Eisai Co., Ltd., personal fees from Fuji Yakuhin Co., Ltd., personal fees from Kowa Pharmaceutical Co., Ltd, personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Medtronic, Inc., personal fees from MSD K.K. a subsidiary of Merck & Co., Inc., personal fees from Nihon Medi-Physics Co.,Ltd., personal fees from Sanofi K.K., personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from ZERIA Pharmaceutical Co., Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Pfizer Japan Inc., personal fees from Taisho Toyama Pharmaceutical Co., Ltd., personal fees from Toa Eiyo LTD., outside the submitted work. Dr. Tsutsui reports personal fees from Novartis Pharma K.K., personal fees from Pfizer Japan Inc., personal fees from Bayer Yakuhin, Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Daiichi Sankyo Co., Ltd., personal fees from MSD K.K., personal fees from Mitsubishi Tanabe Pharm Corp., personal fees from Teijin Pharm Ltd., personal fees from Bristol-Myers Squibb Company, personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from Otsuka Pharmaceuticals Co., Ltd., personal fees from Astellas Parma Inc., outside the submitted work. Dr. Komuro reports grants from Otsuka Pharmaceuticals Co., Ltd., grants and personal fees from Daiichi Sankyo Co., Ltd., grants from Dainippon Sumitomo Pharma Co., Ltd., grants and personal fees from Takeda Pharmaceutical Co., Ltd., grants from Teijin Pharm Ltd., grants from Toa Eiyo LTD., personal fees from Astellas Pharma Inc., personal fees from AstraZeneca K.K., personal fees from MSD K.K., personal fees from Ono Pharmatical Co., Ltd, personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Bayer Yakuhin, Ltd., personal fees from Pfizer Japan Inc., outside the submitted work; Dr. Tsujita reports personal fees from Novartis Pharma K.K., personal fees from Bayer Yakuhin, Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Daiichi Sankyo Co., Ltd., personal fees from MSD K.K., personal fees from Mitsubishi Tanabe Pharm Corp., grants from Teijin Pharm Ltd., personal fees from Bristol-Myers Squibb Company, personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from Otsuka Pharmaceuticals Co., Ltd., personal fees from Astellas Parma Inc., grants from AstraZeneca K.K., personal fees from Sanofi K.K., personal fees from Cardinal Health Japan Inc., personal fees from Goodman Co.,LTD., personal fees from Chugai Pharmaceutical Co, Ltd., personal fees from Boston Scientific Japan K.K., personal fees from Kowa Pharmaceutical Co. Ltd., personal fees from Pfizer Japan Inc., personal fees from Shionogi & Co., outside the submitted work. Dr. Kawakami reports personal fees from Shin Nippon Biomedical Laboratories, Ltd., other from School Health Record Center Co.,Ltd., other from Real World Data, Co., Ltd., grants from Olympus Corporation, grants from Bayer Yakuhin, Ltd., grants from Cmic Co., Ltd., grants from Novartis Pharma K.K., grants from Suntory Beverage & Food Limited, grants from Sumitomo Dainippon Pharma Co., Ltd., grants from Medical Platform Co. Ltd., grants from STELLA PHARMA CORPORATION, grants from Amgen Astellas BioPharma K.K., outside the submitted work. Other authors declare no potential conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 309 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ishii, M., Seki, T., Kaikita, K. et al. Short-term exposure to desert dust and the risk of acute myocardial infarction in Japan: a time-stratified case-crossover study. Eur J Epidemiol (2020) doi:10.1007/s10654-020-00601-y

Download citation

Keywords

  • Air pollution
  • Desert dust
  • Environmental factors
  • Acute myocardial infarction
  • Cardiovascular disease